News

Speaking to Prof. Andrea Rossetti – “Often in life, things happen by chance, but then you have to seize the chance“

2560 1600 Anna Stelling, PhD

Prof. Andrea Rossetti is the head of the Electroencephalography (EEG) and Epilepsy unit of the Neurological department of the University Hospital of Lausanne in Switzerland. He recently published a potentially…

read more

New data on endovascular treatment in patients with cerebral venous thrombosis

2560 1707 Anna Stelling, PhD

Stroke can have several causes, and one of them is cerebral venous thrombosis (CVT), affecting mostly young adult and middle-aged patients.1 The current standard for CVT is anticoagulation treatment with…

read more

Deep brain stimulation in Parkinson’s disease – five-year outcomes

2560 1707 Anna Stelling, PhD

It has been consistently shown that deep brain stimulation (DBS) in combination with medication is superior to medication alone in mid- and advanced-stage Parkinson’s disease (PD).1 These findings also motivated…

read more

Ageing in multiple sclerosis – what do we know?

2846 1601 Anna Stelling, PhD

“Ageing comes with many issues in multiple sclerosis (MS): progression, comorbidities, cognition problems and response to treatment”, Pierre Duquette (Department of Neuroscience, University of Montreal, Canada), the chair of the…

read more

How to promote remyelination in MS

2846 1601 Anne Carter, MA (Cantab)

Strategies to promote remyelination was a hot topic at this year’s virtual ACTRIMS/ECTRIMS joint meeting, with three expert presenters each addressing a different aspect of the subject, including the role…

read more

Does the microbiome have a role in MS?

2846 1600 Anne Carter, MA (Cantab)

Can the bacteria living in your gut influence multiple sclerosis (MS) susceptibility and risk of relapse? That was the question Emmanuelle Waubant (University of California, San Francisco, USA) posed during…

read more

Is disease-modifying treatment in primary progressive multiple sclerosis effective after all?

1703 2560 Anna Stelling, PhD

Until now, several randomised controlled trials and real-world studies could not show the clinical benefit of disease‑modifying treatments (DMTs) in primary progressive multiple sclerosis (PPMS).1-4 However, some recently published results…

read more

Neurofilament light chain levels as a biomarker in multiple sclerosis

1703 2560 Anna Stelling, PhD

It has been previously shown that the neuronal cytoskeletal protein neurofilament light chain (NfL) is released into the blood and cerebrospinal fluid (CSF) upon neuroaxonal injury.1 Hence it was not…

read more

Do hormonal changes influence MS in women?

2400 1600 Anne Carter, MA (Cantab)

There is a paradox in multiple sclerosis (MS): females appear to be more susceptible to the disease than males, but also have a better long-term prognosis. Could this be due…

read more

A reliable blood test for Alzheimer’s disease – is it becoming a reality?

1024 683 Anna Stelling, PhD

The increasing number of patients suffering from dementia caused by Alzheimer’s disease (AD) is a significant challenge for society and requires action by healthcare professionals and researchers worldwide. One important…

read more
Brainwork is supported by unrestricted grants from: